• <optgroup id="dwefb"><li id="dwefb"><del id="dwefb"></del></li></optgroup>

    <acronym id="dwefb"></acronym>
  • <strong id="dwefb"></strong>
  • <ol id="dwefb"><output id="dwefb"></output></ol>
       中  文
      Stock Short Name:Hybio Pharmaceutical | Stock Exchange Code:300199

      The foundation of Guangdong Engineering and Technology R&D Center of Polypeptide Drug (hereafter referred to as Polypeptide Center), a research institute invested by Hybio, is approved by Guangdong Science and Technology Department, Guangdong Development and Reform Commission and Guangdong Economic and Trade Commission. With a professional development team including post-doctors from US and PhDs, Polypeptide Center has built the collaboration with more than 30 colleges, universities and institutes in China. The research platforms of large scale preparation technology, synthesis of new compounds, study of new formulations and drug quality has been established, which meet the GLP standard. Special instruments and equipment, including the automatic peptide-synthesis-system imported from US, Germany, Switzerland and France etc., the system of perfusing chromatography, the large-capacity-purification system and the gas chromatography system, Metrohm ion chromatograph and moisture meter, have been equipped. In current China, it is one of the top peptide-drug-research centers with gathering talents, advanced equipment and the complete industrial system.

      Polypeptide Center successively undertook or participated in more than 20 provincial key projects, including National High-Tech Research and Development Project (863), National “Tenth five” and “Eleventh five” Municipal Science and Technology Project, Project in National Torch Plan, National Major Project for New Drug Innovation and Development, Guangdong Municipal Science and Technology Project, Guangdong Industry-education-research Cooperation Project and Guangdong Major Projects of Breakthroughs in Key Area etc.. Polypeptide Center participated in the development of the national industry standard of polypeptide drug registration and 16 items in the new Chinese pharmacopoeia standard.





      Polypeptide Center has built a peptide database with more than ten thousand kinds of peptides, and has high reputation on the synthesis and quality control of long-chain peptides, modified peptides, cyclic peptides and complicated peptides. It has successively supplied the polypeptides for scientific research to nearly 100 research institutions and enterprises around the world, including Peking University, Tsinghua University, Sichuan University, Lanzhou University, Zhejiang University, Life Science Innovation Center of the Ministry of Sci. & Tech., Academy of Military Medical Science, Sun Yat-Sen University, Hong Kong University of Science and Technology, National Institutes of Health, Harvard University, University of California, University of Oxford, Celtek LLC, SynBioSci, NEP, Cipla, Ranbaxy, Biocan etc.. It has been a R&D base of polypeptide drugs opening to the world.


    1. <optgroup id="dwefb"><li id="dwefb"><del id="dwefb"></del></li></optgroup>

      <acronym id="dwefb"></acronym>
    2. <strong id="dwefb"></strong>
    3. <ol id="dwefb"><output id="dwefb"></output></ol>